COVID-19 Impacts: Heparin Market will Accelerate at a CAGR of almost 3% through 2020-2024 | Increasing Prevalence of Chronic Conditions to Boost Growth | Technavio
Technavio has been monitoring the heparin market and it is poised to grow by USD 941.2 million during 2020-2024, progressing at a CAGR of almost 3% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.
At what rate is the market projected to grow during the forecast period 2020-2024?
Growing at a CAGR of almost 3%, the market growth will accelerate during the forecast period.
What is the key factor driving the market?
Increasing prevalence of chronic conditions is one of the key factors driving the market growth.
Who are the top players in the market?
Aspen Pharmacare Holdings Ltd., Baxter International Inc., Eisai Co. Ltd., Fresenius SE & Co. KGaA, Hikma Pharmaceuticals Plc, Laboratorios Farmaceuticos Rovi SA, Mylan NV, Nanjing King-Friend Biochemical Pharmaceutical Co. Ltd., Pfizer Inc., and Sanofi are some of the major market participants.
Which region is expected to hold the highest market share?
Europe
What is the year-over-year growth rate of the global market?
The year-over year growth rate for 2020 is estimated at 2.72%.
The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. Aspen Pharmacare Holdings Ltd., Baxter International Inc., Eisai Co. Ltd., Fresenius SE & Co. KGaA, Hikma Pharmaceuticals Plc, Laboratorios Farmaceuticos Rovi SA, Mylan NV, Nanjing King-Friend Biochemical Pharmaceutical Co. Ltd., Pfizer Inc., and Sanofi. are some of the major market participants. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
Increasing prevalence of chronic conditions has been instrumental in driving the growth of the market.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. Our heparin market report covers the following areas:
Heparin Market size
Heparin Market trends
Heparin Market analysis
This study identifies the increase in R&D activities and new therapeutic applications of heparin as the prime reasons driving the heparin market growth during the next few years.
Heparin Market 2020-2024: Vendor Analysis
We provide a detailed analysis of vendors operating in the heparin market, including some of the vendors such as Aspen Pharmacare Holdings Ltd., Baxter International Inc., Eisai Co. Ltd., Fresenius SE & Co. KGaA, Hikma Pharmaceuticals Plc, Laboratorios Farmaceuticos Rovi SA, Mylan NV, Nanjing King-Friend Biochemical Pharmaceutical Co. Ltd., Pfizer Inc., and Sanofi. Backed with competitive intelligence and benchmarking, our research reports on the heparin market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Voxtur Analytics Corp. , a North American technology company creating a more transparent and accessible real estate lending ecosystem, is pleased to announce that it has engaged the services of ICP Securities Inc. ("ICP") to provide automated market...
On April 19, 2024, the board of directors of Portland General Electric Company declared a quarterly common stock dividend of $0.50 per share, representing an increase of 5.3%, or $0.10 per share, on an annualized basis.
The company's dividend is...
Adyton Resources Corporation ("Adyton" or the "Company") announces it has closed its previously announced non-brokered private placement offering, pursuant to which it has issued 50,000,000 common shares of the Company ("Shares") at a price of...
Building on a successful phase one in which STChealth proved that the Universal Patient Identifier (UPI)?powered by Experian Health's Universal Identity Manager (UIM) and NCPDP Standardstm?can accurately identify patients across multiple datasets in...
Lion Group Holding Ltd. ("Lion" or "the Company") , the operator of an all-in-one trading platform that offers a wide spectrum of products and services, today announced that on April 18, 2024, it received a delinquency notification letter from the...
Cosmos Health Inc. ("Cosmos Health" or the "Company'') , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor...